<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="case-report" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Dis Ther</journal-id><journal-id journal-id-type="iso-abbrev">Infect Dis Ther</journal-id><journal-id journal-id-type="pmc-domain-id">2527</journal-id><journal-id journal-id-type="pmc-domain">infecdisther</journal-id><journal-title-group><journal-title>Infectious Diseases and Therapy</journal-title></journal-title-group><issn pub-type="ppub">2193-8229</issn><issn pub-type="epub">2193-6382</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11128413</article-id><article-id pub-id-type="pmcid-ver">PMC11128413.1</article-id><article-id pub-id-type="pmcaid">11128413</article-id><article-id pub-id-type="pmcaiid">11128413</article-id><article-id pub-id-type="pmid">38728006</article-id><article-id pub-id-type="doi">10.1007/s40121-024-00981-8</article-id><article-id pub-id-type="publisher-id">981</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>Implementation of AZD7442 (Tixagevimab/Cilgavimab) COVID-19 Pre-exposure Prophylaxis (PrEP) in the Largest Health Maintenance Organization in Israel: Real-world Uptake and Sociodemographic and Clinical Characteristics Across Immunocompromised Patient Groups</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3300-1769</contrib-id><name name-style="western"><surname>Hayek</surname><given-names initials="S">Samah</given-names></name><address><email>samahha@clalit.org.il</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Levy</surname><given-names initials="J">Joseph</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shaham</surname><given-names initials="G">Galit</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dagan</surname><given-names initials="N">Noa</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Serby</surname><given-names initials="D">Danielle</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Duskin-Bitan</surname><given-names initials="H">Hadar</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yarden</surname><given-names initials="A">Adva</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ferreira</surname><given-names initials="C">C&#225;tia</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Livnat</surname><given-names initials="I">Idit</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dube</surname><given-names initials="S">Sabada</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Taylor</surname><given-names initials="S">Sylvia</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Venkatesan</surname><given-names initials="S">Sudhir</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Balicer</surname><given-names initials="RD">Ran D.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Netzer</surname><given-names initials="D">Doron</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Peretz</surname><given-names initials="A">Alon</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04mhzgx49</institution-id><institution-id institution-id-type="GRID">grid.12136.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0546</institution-id><institution>Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medicine, </institution><institution>Tel Aviv University, </institution></institution-wrap>Tel Aviv, Israel </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04zjvnp94</institution-id><institution-id institution-id-type="GRID">grid.414553.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0575 3597</institution-id><institution>Innovation Division, </institution><institution>Clalit Research Institute, Clalit Health Services, </institution></institution-wrap>Tel Aviv, Israel </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.7489.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0511</institution-id><institution>Software and Information Systems Engineering, </institution><institution>Ben Gurion University, </institution></institution-wrap>Be&#8217;er Sheva, Israel </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution>Department of Biomedical Informatics, </institution><institution>Harvard Medical School, </institution></institution-wrap>Boston, MA USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution>The Ivan and Francesca Berkowitz Family Living Laboratory Collaboration, </institution><institution>Harvard Medical School and Clalit Research Institute, </institution></institution-wrap>Boston, MA USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04zjvnp94</institution-id><institution-id institution-id-type="GRID">grid.414553.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0575 3597</institution-id><institution>Clalit Community Division, </institution><institution>Clalit Health Services, </institution></institution-wrap>Tel Aviv, Israel </aff><aff id="Aff7"><label>7</label>Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Kfar-Saba, Israel </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.418152.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0543 9493</institution-id><institution>Vaccines and Immune Therapies Unit, BioPharmaceuticals Medical, </institution><institution>AstraZeneca, </institution></institution-wrap>Wilmington, DE USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.417815.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 5929 4381</institution-id><institution>Epidemiology, Vaccines and Immune Therapies Unit, AstraZeneca, </institution></institution-wrap>Cambridge, UK </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.417815.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 5929 4381</institution-id><institution>Medical Evidence, Vaccines and Immune Therapies Unit, </institution><institution>AstraZeneca, </institution></institution-wrap>Cambridge, UK </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.417815.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 5929 4381</institution-id><institution>Medical and Payer Evidence, BioPharmaceuticals Medical, </institution><institution>AstraZeneca, </institution></institution-wrap>Cambridge, UK </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05tkyf982</institution-id><institution-id institution-id-type="GRID">grid.7489.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0511</institution-id><institution>School of Public Health, Faculty of Health Sciences, </institution><institution>Ben Gurion University of the Negev, </institution></institution-wrap>Be&#8217;er Sheva, Israel </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>5</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2024</year></pub-date><volume>13</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">463358</issue-id><fpage>1379</fpage><lpage>1389</lpage><history><date date-type="received"><day>6</day><month>2</month><year>2024</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>05</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>28</day><month>05</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-28 00:25:14.917"><day>28</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="40121_2024_Article_981.pdf"/><abstract id="Abs1"><sec><title>Introduction</title><p id="Par1">AZD7442 is a combination of two neutralizing antibodies (tixagevimab/cilgavimab) with demonstrated efficacy in reducing the risk of symptomatic coronavirus disease 2019 (COVID-19) among individuals at high risk of severe COVID-19&#8201;&#8804;&#8201;6&#160;months after administration. On February 15, 2022, the Israeli Ministry of Health (IMoH) authorized the administration of 300&#160;mg AZD7442 as pre-exposure prophylaxis (PrEP) against severe acute respiratory syndrome coronavirus 2&#160;infection among immunocompromised individuals aged&#8201;&#8805;&#8201;12&#160;years. This study describes the real-world uptake of AZD7442 in Israel.</p></sec><sec><title>Methods</title><p id="Par2">This descriptive, observational study analyzed data from Israel&#8217;s largest health maintenance organization, Clalit Health Services (CHS). Individuals were assessed for AZD7442 eligibility between February 13 and December 11, 2022, and were included if they were aged&#8201;&#8805;&#8201;12&#160;years, had&#8201;&#8805;&#8201;1&#160;year of continuous CHS membership,&#8201;had&#160;&#8805;&#8201;1 moderate or severe immunocompromising condition, and were eligible for AZD7442 per IMoH recommendations during this time frame.</p></sec><sec><title>Results</title><p id="Par3">Overall, 19,161 AZD7442-eligible individuals with immunocompromising conditions were identified during the study period; 2829 (14.8%) received AZD7442. A higher proportion of individuals receiving AZD7442 were older (aged&#8201;&#8805;&#8201;65&#160;years), male, not current smokers and residents in large cities; required more physician visits (&gt;&#8201;50 visits); and had&#8201;&#8805;&#8201;1 COVID-19 hospitalization over 12&#160;months, while uptake was lowest among ultra-orthodox Jewish individuals. AZD7442 uptake was also higher among individuals with multiple comorbidities (Charlson Comorbidity Index&#8201;&#8805;&#8201;5), including hypertension, diabetes and chronic kidney disease. In specific immunocompromised types, AZD7442 uptake was highest among individuals with lung transplantation (41%), primary immunodeficiency (32%), bone marrow transplantation (29%) and multiple myeloma (25%) or those receiving anti-CD20 therapy (26%) and was lowest in individuals with lymphoma (8%).</p></sec><sec><title>Conclusion</title><p id="Par4">These results show AZD7442 uptake among the eligible population of Israel in 2022 was relatively low, at 14.8%. Uptake was generally higher among immunocompromised individuals who may be perceived to be frail or at highest risk of COVID-19 infection and complications, although at 25&#8211;41%, further improvements in uptake would be more impactful. These results also indicate there is opportunity to expand AZD7442 uptake across immunocompromised groups and ensure more equitable uptake among some other sociodemographic groups. Overall, this study will help inform and reassess future implementation strategies for vulnerable populations.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s40121-024-00981-8.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>AZD7442</kwd><kwd>COVID-19</kwd><kwd>Immunocompromised</kwd><kwd>Israel</kwd><kwd>Pre-exposure prophylaxis</kwd><kwd>Real-world evidence</kwd><kwd>SARS-CoV-2</kwd><kwd>Tixagevimab/cilgavimab</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004325</institution-id><institution>AstraZeneca</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Healthcare Ltd., part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="d33e361"><title>Key Summary Points</title><p id="Par5">
<table-wrap id="Taba" position="float" orientation="portrait"><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="1" rowspan="1">There is little real-world information about the use of non-vaccine prophylaxis for COVID-19.</td></tr><tr><td align="left" colspan="1" rowspan="1">AZD7442 had been administered to patients with immunocompromising conditions in Israel and worldwide prior to the withdrawal of its emergency use authorization.</td></tr><tr><td align="left" colspan="1" rowspan="1">This study sought to identify patterns of AZD7442 uptake in Israel to help optimize the distribution of future pre-exposure prophylaxis to those who remain vulnerable to severe COVID-19 outcomes.</td></tr><tr><td align="left" colspan="1" rowspan="1">Uptake was generally higher among immunocompromised individuals who may be at highest risk of COVID-19 infection and complications.</td></tr><tr><td align="left" colspan="1" rowspan="1">There is opportunity to expand AZD7442 uptake across immunocompromised groups and ensure more equitable uptake among other sociodemographic groups.</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec1"><title>Introduction</title><p id="Par6">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in &gt; 700 million confirmed infections and almost 7 million deaths worldwide since December 2019 [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref>]. The SARS-CoV-2 vaccination campaigns successfully led to a high level of coronavirus disease 2019 (COVID-19) vaccination and have more than halved the potential death toll of COVID-19 globally (before the emergence of the omicron [B.1.1.529] variant), with an estimated 19.8 million COVID-19 deaths averted [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par7">Although the World Health Organization has now declared that COVID-19 is no longer a public health emergency of international concern [<xref ref-type="bibr" rid="CR5">5</xref>], SARS-CoV-2 infections are still occurring. In the 7&#160;days before December 24, 2023, 259,104 new cases were reported globally [<xref ref-type="bibr" rid="CR6">6</xref>]. Furthermore, this figure may underestimate the true extent of isolation and infection because of a reduction in the availability of COVID-19 tests. Immunocompromised (IC) individuals and other high-risk groups are still vulnerable to severe COVID-19 outcomes [<xref ref-type="bibr" rid="CR7">7</xref>]. These groups are not only more likely to have severe COVID-19 outcomes [<xref ref-type="bibr" rid="CR8">8</xref>] but are also more likely to have suboptimal responses to vaccination, leading to protracted infections, delays in primary condition treatment and possible escape variant evolution [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Therefore, these populations will benefit from additional protection.</p><p id="Par8">AZD7442, which comprises two neutralizing monoclonal antibodies (tixagevimab/cilgavimab), was granted emergency use authorization (EUA) as a pre-exposure prophylaxis (PrEP) for COVID-19 by the US Food and Drug Administration (FDA) in December 2021 based on the results of the PROVENT trial [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. AZD7442 was approved at a dose of 300&#160;mg (150&#160;mg tixagevimab/150&#160;mg cilgavimab; later changed to 600&#160;mg [300&#160;mg tixagevimab/300&#160;mg cilgavimab]) for individuals aged&#8201;&#8805;&#8201;12&#160;years and weighing&#8201;&#8805;&#8201;40&#160;kg with moderate to severe immunocompromising conditions, on immunosuppressive medications or treatments, or unable to receive a COVID-19 vaccination [<xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>]. The rollout of AZD7442 was initiated midway through the B.1.1529 (Omicron variant) dominant period (January 10&#8211;March 2, 2022) [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par9">Although AZD7442 has proven efficacy against COVID-19 hospitalization and death [<xref ref-type="bibr" rid="CR12">12</xref>], the EUA was subsequently withdrawn in January 2023 by the FDA when the circulating SARS-CoV-2 variants non-susceptible to AZD7442 in in vitro neutralization assays (BQ.1, BQ.1.1, BF.7, BF.11, BA.5.2.6, BA.4.6, BA.2.75.2, XBB and XBB.1.5) reached&#8201;&#8805;&#8201;90% [<xref ref-type="bibr" rid="CR17">17</xref>]. Based on the FDA ruling, AZD7442 was also withdrawn by the Israeli Ministry of Health (IMoH) and across other countries.</p><p id="Par10">Despite the wide-scale rollout of non-vaccine prophylaxis in recent years, there are few studies reporting their real-world use, particularly in high-risk populations, which could inform and improve future interventions. Understanding patterns of uptake may help to develop public health PrEP utilization policy&#160;and help optimize the distribution of future therapies to those who remain vulnerable to severe COVID-19 outcomes. Here, we report results of an observational study utilizing data from Israel&#8217;s largest health maintenance organization (HMO), Clalit Health Services (CHS), which aimed to determine AZD7442 real-world uptake in Israel among IC individuals and characterize those who received AZD7442, and compare baseline factors among those eligible for AZD7442 who did or did not receive AZD7442.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study Design and Data Source</title><p id="Par11">This descriptive analysis is based on the eVusheld&#160;Assessment reaL wORld effectiveness (VALOR-C19) observational study, which assessed the effectiveness of AZD7442 PrEP in reducing COVID-19 hospitalizations among AZD7442-eligible IC populations in Israel (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05712096">NCT05712096</ext-link>). This paper characterizes AZD7442 uptake in IC individuals eligible for AZD7442 administration as PrEP as per IMoH recommendations.</p><p id="Par12">Israel is a country with national health insurance, and AZD7442 was distributed to eligible individuals through integrated payer-provider HMOs. CHS is the largest HMO in Israel, with &gt; 4.7 million members (~&#8201;53% of the population). Data were obtained from the CHS electronic health record (EHR) database containing inpatient, outpatient and COVID-19 repositories, which was described previously [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par13">In total, the IMoH received 20,104 doses of AZD7442 between February 13 and November 24, 2022. CHS received 8000 of these doses, which were proactively offered to eligible members.</p></sec><sec id="Sec4"><title>Study Population</title><p id="Par14">Individuals were eligible for inclusion if they were aged&#8201;&#8805;&#8201;12&#160;years and fulfilled the IMoH criteria for AZD7442 PreP during the study period (February 13 to December 31, 2022), defined as having at least one comorbidity or condition causing severe immunosuppression (i.e., chimeric antigen receptor T-cell therapy [CAR-T], solid organ transplant [SOT], autologous or allogenic bone marrow transplant [within the previous year if allogenic], hypogammaglobulinemia, active lymphoma, active multiple myeloma, diagnosis of chronic lymphocytic leukemia [CLL] or receiving treatment for CLL, and B-cell-depleting therapies). The full list of disease definitions is included in Supplemental Table <xref rid="MOESM1" ref-type="media">S1</xref>. Exclusion criteria included documented history of a positive SARS-CoV-2 polymerase chain reaction or antigen test prior to AZD7442 administration. Lack of SARS-CoV-2 test history was not exclusionary.</p></sec><sec id="Sec5"><title>Study Variables</title><p id="Par15">Key demographic and clinical characteristics, including immunocompromising condition, select comorbidities (e.g., heart disease, type 2 diabetes, hypertension, etc.) up to 5&#160;years prior to the date of AZD7442 administration, medication use and number of physicians visits a year prior to the index date, were extracted from EHRs.</p></sec><sec id="Sec6"><title>Statistical Analysis</title><p id="Par16">The demographic and clinical characteristics of the total study population and by AZD7224 recipient or non-recipient status were described using summary statistics: number and percentage for categorical variables and median and interquartile range for count variables. Statistical analyses were performed using R software, version 4.2.1.</p></sec><sec id="Sec7"><title>Ethical Approval</title><p id="Par17">This study used de-identified patient data and was approved by the Clalit Health Services institutional review board.</p></sec></sec><sec id="Sec8"><title>Results</title><p id="Par18">In total, 19,161 IC individuals eligible for AZD7442 PrEP between February 13 and November 24, 2022, were identified from the CHS database. Among these, AZD7442 uptake was 14.8% (<italic toggle="yes">n</italic>&#8201;=&#8201;2829 received AZD7442). The distribution of AZD7442 uptake by month is presented in supplemental Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Uptake of AZD7442 by <bold>a</bold> immunocompromising condition and <bold>b</bold> number of immunocompromising conditions. <italic toggle="yes">CLL</italic> chronic lymphocytic leukemia, <italic toggle="yes">CAR-T</italic> chimeric antigen receptor T-cell, <italic toggle="yes">GVHD</italic> graft versus host disease, <italic toggle="yes">SOT</italic> solid organ transplant</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="40121_2024_981_Fig1_HTML.jpg"/></fig></p><p id="Par19">Baseline characteristics for the overall eligible population and by AZD7442 recipient status are shown in Table&#160;<xref rid="Tab1" ref-type="table">1</xref> and Supplemental Tables S2&#8211;4. Among the total eligible population, individuals were older (54% were aged&#8201;&#8805;&#8201;65&#160;years) and had multiple comorbidities (66% had a Charlson Comorbidity Index score&#8201;&#8805;&#8201;5), and the most common IC type was lymphoma (43%). When categorized by AZD7442 status and compared with AZD7442 non-recipients, a higher proportion of AZD7442 recipients were aged&#8201;&#8805;&#8201;65&#160;years, not current smokers, had comorbidities (e.g., hypertension, diabetes, chronic kidney disease) and were organ transplant recipients (Table&#160;<xref rid="Tab1" ref-type="table">1</xref> and Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Overall, AZD7442 uptake increased with an increased number of comorbidities (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Baseline demographics and AZD7442 uptake</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">AZD7442 recipient (<italic toggle="yes">N</italic>&#8201;=&#8201;2829)</th><th align="left" colspan="1" rowspan="1">Non-AZD7442 recipient (<italic toggle="yes">N</italic>&#8201;=&#8201;16,331)</th><th align="left" colspan="1" rowspan="1">Total number with each characteristic (total population <italic toggle="yes">N</italic>&#8201;=&#8201;19,160), <italic toggle="yes">n</italic></th><th align="left" colspan="1" rowspan="1"/></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Characteristic, <italic toggle="yes">n</italic> (%)<sup>a</sup></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">AZD7442 uptake per characteristic (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Age, years,&#160;median (IQR)</td><td char="(" align="char" colspan="1" rowspan="1">68 (58&#8211;74)</td><td align="left" colspan="1" rowspan="1">66 (51&#8211;75)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Female</td><td char="(" align="char" colspan="1" rowspan="1">1196 (42)</td><td align="left" colspan="1" rowspan="1">7880 (48)</td><td align="left" colspan="1" rowspan="1">9076</td><td align="left" colspan="1" rowspan="1">13</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Male</td><td char="(" align="char" colspan="1" rowspan="1">1633 (58)</td><td align="left" colspan="1" rowspan="1">8451 (52)</td><td align="left" colspan="1" rowspan="1">10,084</td><td align="left" colspan="1" rowspan="1">16</td></tr><tr><td align="left" colspan="1" rowspan="1">Obese (BMI&#8201;&#8805;&#8201;30&#160;kg/m<sup>2</sup>)</td><td char="(" align="char" colspan="1" rowspan="1">627 (22)</td><td align="left" colspan="1" rowspan="1">4108 (25)</td><td align="left" colspan="1" rowspan="1">4735</td><td align="left" colspan="1" rowspan="1">13</td></tr><tr><td align="left" colspan="1" rowspan="1">Currently smokes</td><td char="(" align="char" colspan="1" rowspan="1">219 (88)</td><td align="left" colspan="1" rowspan="1">2082 (13)</td><td align="left" colspan="1" rowspan="1">2301</td><td align="left" colspan="1" rowspan="1">10</td></tr><tr><td align="left" colspan="1" rowspan="1">Comorbidities<sup>b</sup></td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Hypertension</td><td char="(" align="char" colspan="1" rowspan="1">1553 (55)</td><td align="left" colspan="1" rowspan="1">7605 (47)</td><td align="left" colspan="1" rowspan="1">9158</td><td align="left" colspan="1" rowspan="1">17</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;CHF</td><td char="(" align="char" colspan="1" rowspan="1">368 (13)</td><td align="left" colspan="1" rowspan="1">2117 (13)</td><td align="left" colspan="1" rowspan="1">2485</td><td align="left" colspan="1" rowspan="1">15</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Other cardiovascular diseases</td><td char="(" align="char" colspan="1" rowspan="1">1333 (47)</td><td align="left" colspan="1" rowspan="1">6743 (41)</td><td align="left" colspan="1" rowspan="1">8076</td><td align="left" colspan="1" rowspan="1">17</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Diabetes</td><td char="(" align="char" colspan="1" rowspan="1">885 (31)</td><td align="left" colspan="1" rowspan="1">4293 (26)</td><td align="left" colspan="1" rowspan="1">5178</td><td align="left" colspan="1" rowspan="1">17</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Asthma</td><td char="(" align="char" colspan="1" rowspan="1">253 (9)</td><td align="left" colspan="1" rowspan="1">1408 (9)</td><td align="left" colspan="1" rowspan="1">1661</td><td align="left" colspan="1" rowspan="1">15</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;COPD</td><td char="(" align="char" colspan="1" rowspan="1">187 (7)</td><td align="left" colspan="1" rowspan="1">703 (4)</td><td align="left" colspan="1" rowspan="1">890</td><td align="left" colspan="1" rowspan="1">21</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Chronic liver disease</td><td char="(" align="char" colspan="1" rowspan="1">705 (25)</td><td align="left" colspan="1" rowspan="1">3689 (23)</td><td align="left" colspan="1" rowspan="1">4394</td><td align="left" colspan="1" rowspan="1">16</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Chronic kidney disease</td><td char="(" align="char" colspan="1" rowspan="1">1243 (44)</td><td align="left" colspan="1" rowspan="1">5711 (35)</td><td align="left" colspan="1" rowspan="1">6954</td><td align="left" colspan="1" rowspan="1">18</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Chronic neurological disease</td><td char="(" align="char" colspan="1" rowspan="1">230 (8)</td><td align="left" colspan="1" rowspan="1">1340 (8)</td><td align="left" colspan="1" rowspan="1">1570</td><td align="left" colspan="1" rowspan="1">15</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Anxiety/depression</td><td char="(" align="char" colspan="1" rowspan="1">67 (2)</td><td align="left" colspan="1" rowspan="1">397 (2)</td><td align="left" colspan="1" rowspan="1">464</td><td align="left" colspan="1" rowspan="1">14</td></tr><tr><td align="left" colspan="1" rowspan="1">Number of prior physician visits, median (IQR)</td><td char="(" align="char" colspan="1" rowspan="1">65 (46&#8211;90)</td><td align="left" colspan="1" rowspan="1">45 (28&#8211;66)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;0&#8211;50</td><td char="(" align="char" colspan="1" rowspan="1">851 (30)</td><td align="left" colspan="1" rowspan="1">9506 (58)</td><td align="left" colspan="1" rowspan="1">10,357</td><td align="left" colspan="1" rowspan="1">8</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&gt;&#8201;50</td><td char="(" align="char" colspan="1" rowspan="1">1978 (70)</td><td align="left" colspan="1" rowspan="1">6825 (42)</td><td align="left" colspan="1" rowspan="1">8803</td><td align="left" colspan="1" rowspan="1">22</td></tr><tr><td align="left" colspan="1" rowspan="1">Number of prior COVID-19 hospitalizations, median (IQR)</td><td char="(" align="char" colspan="1" rowspan="1">1 (0&#8211;2)</td><td align="left" colspan="1" rowspan="1">0 (0&#8211;1)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;0&#8211;10</td><td char="(" align="char" colspan="1" rowspan="1">2802 (99)</td><td align="left" colspan="1" rowspan="1">16,199 (99)</td><td align="left" colspan="1" rowspan="1">19,001</td><td align="left" colspan="1" rowspan="1">15</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#8805;&#8201;11</td><td char="(" align="char" colspan="1" rowspan="1">27 (&lt;&#8201;1)</td><td align="left" colspan="1" rowspan="1">132 (&lt;&#8201;1)</td><td align="left" colspan="1" rowspan="1">159</td><td align="left" colspan="1" rowspan="1">17</td></tr><tr><td align="left" colspan="1" rowspan="1">Number of dispensed prescriptions</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;0&#8211;10</td><td char="(" align="char" colspan="1" rowspan="1">1606 (57)</td><td align="left" colspan="1" rowspan="1">12,341 (77)</td><td align="left" colspan="1" rowspan="1">13,947</td><td align="left" colspan="1" rowspan="1">12</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#8805;&#8201;11</td><td char="(" align="char" colspan="1" rowspan="1">1223 (43)</td><td align="left" colspan="1" rowspan="1">3990 (24)</td><td align="left" colspan="1" rowspan="1">5213</td><td align="left" colspan="1" rowspan="1">24</td></tr><tr><td align="left" colspan="1" rowspan="1">Number of prior COVID-19 vaccinations</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;0</td><td char="(" align="char" colspan="1" rowspan="1">40 (1)</td><td align="left" colspan="1" rowspan="1">1562 (10)</td><td align="left" colspan="1" rowspan="1">1602</td><td align="left" colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;1</td><td char="(" align="char" colspan="1" rowspan="1">47 (2)</td><td align="left" colspan="1" rowspan="1">555 (3)</td><td align="left" colspan="1" rowspan="1">602</td><td align="left" colspan="1" rowspan="1">8</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;2</td><td char="(" align="char" colspan="1" rowspan="1">203 (7)</td><td align="left" colspan="1" rowspan="1">1848 (11)</td><td align="left" colspan="1" rowspan="1">2051</td><td align="left" colspan="1" rowspan="1">10</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#8805;&#8201;3</td><td char="(" align="char" colspan="1" rowspan="1">2539 (90)</td><td align="left" colspan="1" rowspan="1">12,366 (76)</td><td align="left" colspan="1" rowspan="1">14,905</td><td align="left" colspan="1" rowspan="1">17</td></tr><tr><td align="left" colspan="1" rowspan="1">Charlson Comorbidity Index score</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;0</td><td char="(" align="char" colspan="1" rowspan="1">53 (2)</td><td align="left" colspan="1" rowspan="1">500 (3)</td><td align="left" colspan="1" rowspan="1">553</td><td align="left" colspan="1" rowspan="1">10</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;1</td><td char="(" align="char" colspan="1" rowspan="1">78 (3)</td><td align="left" colspan="1" rowspan="1">393 (2)</td><td align="left" colspan="1" rowspan="1">471</td><td align="left" colspan="1" rowspan="1">17</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;2</td><td char="(" align="char" colspan="1" rowspan="1">187 (77)</td><td align="left" colspan="1" rowspan="1">1539 (9)</td><td align="left" colspan="1" rowspan="1">1726</td><td align="left" colspan="1" rowspan="1">12</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;3</td><td char="(" align="char" colspan="1" rowspan="1">240 (88)</td><td align="left" colspan="1" rowspan="1">1473 (9)</td><td align="left" colspan="1" rowspan="1">1713</td><td align="left" colspan="1" rowspan="1">14</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;4</td><td char="(" align="char" colspan="1" rowspan="1">285 (10)</td><td align="left" colspan="1" rowspan="1">1728 (11)</td><td align="left" colspan="1" rowspan="1">2013</td><td align="left" colspan="1" rowspan="1">14</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#8805;&#8201;5</td><td char="(" align="char" colspan="1" rowspan="1">1979 (70)</td><td align="left" colspan="1" rowspan="1">10,640 (65)</td><td align="left" colspan="1" rowspan="1">12,619</td><td align="left" colspan="1" rowspan="1">16</td></tr></tbody></table><table-wrap-foot><p>Further baseline characteristics are in the supplementary materials</p><p><italic toggle="yes">BMI</italic> body mass index, <italic toggle="yes">CAR</italic> chimeric antigen receptor, <italic toggle="yes">CHF</italic> congestive heart failure, <italic toggle="yes">COPD</italic> chronic obstructive pulmonary disease, <italic toggle="yes">GVHD</italic> graft versus host disease, <italic toggle="yes">IQR</italic> interquartile range</p><p><sup>a</sup>Unless stated otherwise</p><p><sup>b</sup>Not mutually exclusive</p></table-wrap-foot></table-wrap></p><p id="Par20">When comparing across IC types, AZD7442 uptake was highest in lung transplant recipients (41%), followed by individuals with primary immunodeficiency (32%) and bone marrow transplant recipients (29%) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). AZD7442 uptake was lowest in individuals with lymphoma (8%) and&#8201;&lt;&#8201;20% in individuals with SOT, CAR-T/graft versus host disease and CLL. The full characteristics for AZD7442 recipients and non-recipients by immunocompromising condition are shown in Supplemental Tables S2&#8211;S4.</p><p id="Par21">According to sociodemographic factors, AZD7442 uptake was lowest among ultra-Orthodox Jewish individuals versus the general population and Arab population (7% vs 16% vs 15%, respectively) and highest in residents of large cities versus small cities (16% vs 13%, respectively) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). When analyzed by vaccination status, uptake was highest in individuals with&#8201;&#8805;&#8201;3 previous COVID-19 vaccinations (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Uptake of AZD7442 by <bold>a</bold> age, <bold>b</bold> previous physician visits over the year up to the index date, <bold>c</bold> sector and <bold>d</bold> residence type</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="40121_2024_981_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec9"><title>Discussion</title><p id="Par22">Our study indicates the uptake of AZD7442 among eligible individuals in Israel was relatively low at&#8201;~&#8201;15%. This is consistent with previous reports from the two largest Israeli HMOs, CHS and Maccabi HealthCare Services (MHS; second largest HMO in Israel), where AZD7442 uptake ranged from 9 to 16% over a similar time frame [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. The distribution of AZD7442 to all CHS districts was based on demand, and low uptake was not due to a shortage of supply. It is possible that the structure and organization of HMOs within Israel may have influenced the uptake of AZD7442. Within CHS, AZD7442 administration was managed by the community division, with eligible individuals offered AZD7442 PreP via their primary care clinics. Although eligible individuals were closely managed in the outpatient clinics of general hospitals, the IMoH had not delineated the role of hospitals in the administration of AZD7442. Additionally, only a few hospitals participated in a patient outreach effort by the CHS community division. These factors may explain the relatively low rates of AZD7442 administration to eligible individuals.</p><p id="Par23">Uptake varied widely across different populations, consistent with previous studies using the CHS and MHS databases [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. High uptake in individuals with comorbidities, increased physician visits at baseline and high numbers of dispensed prescriptions suggest that AZD7442 was administered to more frail individuals. Uptake was also high in individuals who were vaccinated with&#8201;&#8805;&#8201;3 doses of the COVID-19 vaccine and previously hospitalized with COVID-19, which may indicate&#160;that those perceived to be at higher risk of severe COVID-19 were more likely to receive PrEP.</p><p id="Par24">Sociodemographics revealed AZD7442 uptake was higher in males versus females, and lower in ultra-orthodox Jewish than Arab individuals, with uptake highest in the rest of the population. This is contrary to previous reports where AZD7442 uptake was higher in ultra-Orthodox Jewish individuals [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Reports on non-COVID-19 vaccine uptake among children show Arab individuals are more likely to be vaccinated than ultra-orthodox Jewish individuals, although at a lower rate in both than the rest of the population, a trend also observed with COVID-19 vaccine uptake [<xref ref-type="bibr" rid="CR22">22</xref>&#8211;<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par25">Across immunocompromising conditions, AZD7442 uptake was highest (41%) among individuals with lung transplants and lowest among individuals with lymphoma (8%), despite lymphoma being the most common IC type among the eligible population. Lower uptake of AZD7442 among individuals with lymphoma than in those with other immunocompromising conditions has been observed in another study in Israel; the reasons for this lower uptake are unclear and should be elucidated in future investigations [<xref ref-type="bibr" rid="CR21">21</xref>]. In Israel, lung transplant recipients are almost exclusively managed in one CHS hospital, which may explain the high AZD7442 uptake among this population as these individuals were managed by the same healthcare team. Although previous studies did not report lung transplants specifically, the trend in uptake in overall SOT recipients presented here aligns with these studies [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par26">The results presented here highlight the low uptake of AZD7742 in eligible IC individuals, especially in certain subgroups. Understanding the factors underlying these lower-than-expected uptake rates may help inform future non-vaccine PrEP rollout strategies. This study also suggests improving the alignment between the CHS community division and the hospital clinics in managing AZD7442 distribution to eligible individuals. This may allow greater uptake, which could have implications for HMOs other than CHS, as well as for those beyond Israel.</p><p id="Par27">Strengths include that this study was undertaken using a database from the largest HMO in Israel, representing&#8201;&gt;&#8201;50% of the population. This database is complete and includes a large number of individuals with immunocompromising conditions, and the results reported here align with a previous study in the second largest HMO. We therefore believe these results are a close reflection of the overall population.</p><p id="Par28">Limitations of the study include that accuracy of results is dependent on the availability and accuracy of information entered into EHRs. We report only descriptive analyses, limiting conclusions on whether specific baseline factors are independently associated with AZD7442 update; further statistical analysis would be needed to investigate this.</p></sec><sec id="Sec10"><title>Conclusions</title><p id="Par29">These findings highlight low uptake of AZD7442 among a population vulnerable to COVID-19. As the IC populations remain at high risk of severe COVID-19 outcomes, the results presented here may provide valuable information for targeting future interventions, particularly next-generation COVID-19 PrEP, toward the most-at-risk populations. These results may also serve as a call to action to consider how rollout is managed for at-risk groups, regardless of the type of intervention.</p></sec><sec sec-type="supplementary-material"><sec id="Sec11"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="40121_2024_981_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file1 (PDF 466 kb)</p></caption></media></supplementary-material></p></sec></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><sec id="FPar3"><title>Medical Writing, Editorial, and Other Assistance</title><p id="Par30">Medical writing support was provided by Flint Stevenson-Jones, PhD, of Parexel, which was in accordance with Good Publication Practice 2022 guidelines and funded by AstraZeneca.</p></sec></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>Samah Hayek, Joseph Levy, Galit Shaham, Noa Dagan, Idit Livnat, Sabada Dube, Sylvia Taylor, Sudhir Venkatesan and Ran D. Balicer conceived and designed the study. Joseph Levy and Galit Shaham participated in data extraction and analysis. Danielle Serby, Hadar Duskin-Bitan, Doron Netzer and Alon Peretz contributed to data collection. Samah Hayek, Joseph Levy, Galit Shaham, Noa Dagan, Idit Livnat, Sabada Dube, Sylvia Taylor, Sudhir Venkatesan, Ran D. Balicer and Alon Peretz wrote the manuscript. Noa Dagan, Danielle Serby, Hadar Duskin-Bitan, Ran D. Balicer, Doron Netzer and Alon Peretz provided clinical guidance. All authors critically reviewed the manuscript and decided to proceed with publication.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study, and the journal&#8217;s Rapid Service fee, was funded by AstraZeneca.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>National and organizational data privacy policies prohibit the sharing of individual-level data, such as those used for this study, even if anonymized.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of Interest</title><p id="Par31">Samah Hayek, Galit Shaham, Noa Dagan, Danielle Serby, Hadar Duskin-Bitan, Ran D. Balicer, Doron Netzer and Alon Peretz are employees of Clalit Health Services. Joseph Levy was an employee of Clalit Health Services at the time of this study and manuscript development; Dr Levy&#8217;s current affiliation is the Hebrew University of Jerusalem. Clalit Research Institute received funding from AstraZeneca to support execution of this study. Institutional grants to Clalit Research Institute from Pfizer outside the submitted work and unrelated to COVID-19, with no direct or indirect personal benefits. Adva Yarden, C&#225;tia Ferreira, Idit Livnat, Sabada Dube, Sylvia Taylor and Sudhir Venkatesan are employees of, and hold or may hold stock in, AstraZeneca.</p></notes><notes id="FPar2"><title>Ethical Approval</title><p id="Par32">This study used de-identified patient data and was approved by the Clalit Health Services institutional review board.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Johns Hopkins University &amp; Medicine. COVID-19 DashBoard [Internet]. 2022. [cited January 12, 2022]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://gisanddata.maps.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6">https://gisanddata.maps.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6</ext-link>. Accessed 12 Apr 2024.</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Worldometer. COVID-19 coronavirus pandemic. [Internet]. 2022. [cited April 25, 2022]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.worldometers.info/coronavirus/">https://www.worldometers.info/coronavirus/</ext-link>. Accessed 25 Apr 2022.</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B</given-names></name><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><etal/></person-group><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>8</issue><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id><pub-id pub-id-type="pmid">31978945</pub-id><pub-id pub-id-type="pmcid">PMC7092803</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watson</surname><given-names>OJ</given-names></name><name name-style="western"><surname>Barnsley</surname><given-names>G</given-names></name><name name-style="western"><surname>Toor</surname><given-names>J</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>AB</given-names></name><name name-style="western"><surname>Winskill</surname><given-names>P</given-names></name><name name-style="western"><surname>Ghani</surname><given-names>AC</given-names></name></person-group><article-title>Global impact of the first year of COVID-19 vaccination: a mathematical modelling study</article-title><source>Lancet Infect Dis</source><year>2022</year><volume>22</volume><issue>9</issue><fpage>1293</fpage><lpage>1302</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00320-6</pub-id><pub-id pub-id-type="pmid">35753318</pub-id><pub-id pub-id-type="pmcid">PMC9225255</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">World Health Organization. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. [Internet]. 2023. [cited December 28, 2023]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic">https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic</ext-link>. Accessed 12 Apr 2024.</mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">World Health Organization. WHO COVID-19 dashboard. [Internet]. 2023 [cited June 1, 2023]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://covid19.who.int/">https://covid19.who.int/</ext-link>. Accessed 12 Apr 2024.</mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahremand</surname><given-names>T</given-names></name><name name-style="western"><surname>Yao</surname><given-names>JA</given-names></name><name name-style="western"><surname>Mill</surname><given-names>C</given-names></name><name name-style="western"><surname>Piszczek</surname><given-names>J</given-names></name><name name-style="western"><surname>Grant</surname><given-names>JM</given-names></name><name name-style="western"><surname>Smolina</surname><given-names>K</given-names></name></person-group><article-title>COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada</article-title><source>Lancet Reg Health Am</source><year>2023</year><volume>20</volume><fpage>100461</fpage><pub-id pub-id-type="pmid">36890850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lana.2023.100461</pub-id><pub-id pub-id-type="pmcid">PMC9987330</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williamson</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Walker</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Bhaskaran</surname><given-names>K</given-names></name><name name-style="western"><surname>Bacon</surname><given-names>S</given-names></name><name name-style="western"><surname>Bates</surname><given-names>C</given-names></name><name name-style="western"><surname>Morton</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Factors associated with COVID-19-related death using OpenSAFELY</article-title><source>Nature</source><year>2020</year><volume>584</volume><issue>7821</issue><fpage>430</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2521-4</pub-id><pub-id pub-id-type="pmid">32640463</pub-id><pub-id pub-id-type="pmcid">PMC7611074</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shoham</surname><given-names>S</given-names></name><name name-style="western"><surname>Batista</surname><given-names>C</given-names></name><name name-style="western"><surname>Amor</surname><given-names>YB</given-names></name><name name-style="western"><surname>Ergonul</surname><given-names>O</given-names></name><name name-style="western"><surname>Hassanain</surname><given-names>M</given-names></name><name name-style="western"><surname>Hotez</surname><given-names>P</given-names></name><etal/></person-group><article-title>Vaccines and therapeutics for immunocompromised patients with COVID-19</article-title><source>EClinicalMedicine</source><year>2023</year><volume>59</volume><fpage>101965</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2023.101965</pub-id><pub-id pub-id-type="pmid">37070102</pub-id><pub-id pub-id-type="pmcid">PMC10091856</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>ARYB</given-names></name><name name-style="western"><surname>Wong</surname><given-names>SY</given-names></name><name name-style="western"><surname>Chai</surname><given-names>LYA</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MX</given-names></name><name name-style="western"><surname>Muthiah</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis</article-title><source>BMJ</source><year>2022</year><volume>376</volume><fpage>e068632</fpage><pub-id pub-id-type="doi">10.1136/bmj-2021-068632</pub-id><pub-id pub-id-type="pmid">35236664</pub-id><pub-id pub-id-type="pmcid">PMC8889026</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals. [Internet]. 2021. [cited December 28, 2023]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-antibodies-pre-exposure">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-antibodies-pre-exposure</ext-link>. Accessed 12 Apr 2024.</mixed-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levin</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Ustianowski</surname><given-names>A</given-names></name><name name-style="western"><surname>De Wit</surname><given-names>S</given-names></name><name name-style="western"><surname>Launay</surname><given-names>O</given-names></name><name name-style="western"><surname>Avila</surname><given-names>M</given-names></name><name name-style="western"><surname>Templeton</surname><given-names>A</given-names></name><etal/></person-group><article-title>Intramuscular AZD7442 (tixagevimab&#8211;cilgavimab) for prevention of Covid-19</article-title><source>N Engl J Med</source><year>2022</year><volume>386</volume><issue>23</issue><fpage>2188</fpage><lpage>2200</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2116620</pub-id><pub-id pub-id-type="pmid">35443106</pub-id><pub-id pub-id-type="pmcid">PMC9069994</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">AstraZeneca. Evusheld (formerly AZD7442) long-acting antibody combination authorised for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19. [Internet]. 2021. [cited December 28, 2023]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19.html#">https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19.html#</ext-link>. Accessed 12 Apr 2024.</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kmietowicz</surname><given-names>Z</given-names></name></person-group><article-title>Covid-19: monoclonal antibodies authorised in US as alternative to vaccines for certain groups</article-title><source>BMJ</source><year>2021</year><volume>375</volume><fpage>n3064</fpage><pub-id pub-id-type="doi">10.1136/bmj.n3064</pub-id><pub-id pub-id-type="pmid">34893506</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Israeli Ministry of Health. The Ministry of Health has instructed the HMOs to vaccinated immunosuppressed individuals with AstraZeneca's Evusheld vaccine. [Internet]. 2022. [cited December 28, 2023]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gov.il/en/departments/news/15022022-02">https://www.gov.il/en/departments/news/15022022-02</ext-link>. Accessed 12 Apr 2024.</mixed-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bar-On</surname><given-names>YM</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mandel</surname><given-names>M</given-names></name><name name-style="western"><surname>Bodenheimer</surname><given-names>O</given-names></name><name name-style="western"><surname>Amir</surname><given-names>O</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>L</given-names></name><etal/></person-group><article-title>Protection by a fourth dose of BNT162b2 against Omicron in Israel</article-title><source>N Engl J Med</source><year>2022</year><volume>386</volume><issue>18</issue><fpage>1712</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2201570</pub-id><pub-id pub-id-type="pmid">35381126</pub-id><pub-id pub-id-type="pmcid">PMC9006780</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">US Food and Drug Administration. FDA announces Evusheld is not currently authorized for emergency use in the U.S. [Internet]. 2023 [cited June 1, 2023]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us">https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us</ext-link>. Accessed 12 Apr 2024.</mixed-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barda</surname><given-names>N</given-names></name><name name-style="western"><surname>Dagan</surname><given-names>N</given-names></name><name name-style="western"><surname>Ben-Shlomo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kepten</surname><given-names>E</given-names></name><name name-style="western"><surname>Waxman</surname><given-names>J</given-names></name><name name-style="western"><surname>Ohana</surname><given-names>R</given-names></name><etal/></person-group><article-title>Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><issue>12</issue><fpage>1078</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2110475</pub-id><pub-id pub-id-type="pmid">34432976</pub-id><pub-id pub-id-type="pmcid">PMC8427535</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dagan</surname><given-names>N</given-names></name><name name-style="western"><surname>Barda</surname><given-names>N</given-names></name><name name-style="western"><surname>Kepten</surname><given-names>E</given-names></name><name name-style="western"><surname>Miron</surname><given-names>O</given-names></name><name name-style="western"><surname>Perchik</surname><given-names>S</given-names></name><name name-style="western"><surname>Katz</surname><given-names>MA</given-names></name><etal/></person-group><article-title>BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><issue>15</issue><fpage>1412</fpage><lpage>1423</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2101765</pub-id><pub-id pub-id-type="pmid">33626250</pub-id><pub-id pub-id-type="pmcid">PMC7944975</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Najjar-Debbiny</surname><given-names>R</given-names></name><name name-style="western"><surname>Gronich</surname><given-names>N</given-names></name><name name-style="western"><surname>Weber</surname><given-names>G</given-names></name><name name-style="western"><surname>Stein</surname><given-names>N</given-names></name><name name-style="western"><surname>Saliba</surname><given-names>W</given-names></name></person-group><article-title>Effectiveness of Evusheld in immunocompromised patients: propensity score&#8211;matched analysis</article-title><source>Clin Infect Dis</source><year>2023</year><volume>76</volume><issue>6</issue><fpage>1067</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1093/cid/ciac855</pub-id><pub-id pub-id-type="pmid">36310534</pub-id><pub-id pub-id-type="pmcid">PMC9623900</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Kertes J, Shapiro Ben David S, Engel-Zohar N, Rosen K, Hemo B, Kantor A, et al. Association between AZD7442 (tixagevimab-cilgavimab) administration and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospitalization, and mortality. Clin Infect Dis. 2023;76(3):e126&#8211;e32.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciac625</pub-id><pub-id pub-id-type="pmcid">PMC9384583</pub-id><pub-id pub-id-type="pmid">35904210</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muhsen</surname><given-names>K</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>D</given-names></name></person-group><article-title>Rotavirus vaccines in Israel: uptake and impact</article-title><source>Hum Vaccin Immunother</source><year>2017</year><volume>13</volume><issue>7</issue><fpage>1722</fpage><lpage>1727</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1297908</pub-id><pub-id pub-id-type="pmid">28281866</pub-id><pub-id pub-id-type="pmcid">PMC5512754</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorelik</surname><given-names>Y</given-names></name><name name-style="western"><surname>Anis</surname><given-names>E</given-names></name><name name-style="western"><surname>Edelstein</surname><given-names>M</given-names></name></person-group><article-title>Inequalities in initiation of COVID19 vaccination by age and population group in Israel-December 2020-July 2021</article-title><source>Lancet Reg Health Eur</source><year>2022</year><volume>12</volume><fpage>100234</fpage><pub-id pub-id-type="doi">10.1016/j.lanepe.2021.100234</pub-id><pub-id pub-id-type="pmid">34746908</pub-id><pub-id pub-id-type="pmcid">PMC8556198</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muhsen</surname><given-names>K</given-names></name><name name-style="western"><surname>Na'aminh</surname><given-names>W</given-names></name><name name-style="western"><surname>Lapidot</surname><given-names>Y</given-names></name><name name-style="western"><surname>Goren</surname><given-names>S</given-names></name><name name-style="western"><surname>Amir</surname><given-names>Y</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S</given-names></name><etal/></person-group><article-title>A nationwide analysis of population group differences in the COVID-19 epidemic in Israel, February 2020&#8211;February 2021</article-title><source>Lancet Reg Health Eur</source><year>2021</year><volume>7</volume><fpage>100130</fpage><pub-id pub-id-type="doi">10.1016/j.lanepe.2021.100130</pub-id><pub-id pub-id-type="pmid">34109321</pub-id><pub-id pub-id-type="pmcid">PMC8177966</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>